Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 1.6494 million shares on February 13, with a total net increase of 467,400 shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net increases in holdings by southbound funds, totaling 8.016 million shares [1] - As of now, southbound funds hold 73.0944 million shares of Baize Medical, representing 5.54% of the company's total issued ordinary shares [1] Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - Services provided include cancer diagnosis, treatment, rehabilitation, end-of-life care, early cancer screening, cancer vaccination, and health management services for potential healthy populations [1] - The company primarily operates in the Chinese market [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 1.4748 million shares on February 12, with a total net reduction of 1.5456 million shares over the past five trading days [1] - Over the last 20 trading days, there have been 10 days of net increases in southbound fund holdings, totaling 5.3742 million shares [1] - As of now, southbound funds hold 71.445 million shares of Baize Medical, representing 5.41% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Core Insights - Tencent Holdings (00700), Southern Hang Seng Technology (03033), and Xiaomi Group-W (01810) ranked as the top three in net inflow of southbound funds, with net inflows of 1.792 billion, 0.571 billion, and 0.412 billion respectively [1] - The top three in net outflow of southbound funds were Yingfu Fund (02800), Hang Seng China Enterprises (02828), and Kuaishou-W (01024), with net outflows of -4.553 billion, -1.380 billion, and -0.576 billion respectively [1] - In terms of net inflow ratio, Huaxia Hang Seng Technology (03088), Southern East Selection (03441), and Anhui Wantuo Expressway (00995) led the market with ratios of 90.53%, 74.02%, and 68.27% respectively [1] - The top three in net outflow ratio were Southern Hong Kong Stock Connect (03432), Fuyao Glass (06865), and Baize Medical (02609) with ratios of -100.00%, -59.27%, and -53.09% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.792 billion, representing a 12.21% increase, closing at 560.000 (+2.28%) [2] - Southern Hang Seng Technology (03033) saw a net inflow of 0.571 billion, with a 6.77% increase, closing at 5.300 (+1.34%) [2] - Xiaomi Group-W (01810) recorded a net inflow of 0.412 billion, with a 9.45% increase, closing at 35.200 (+0.06%) [2] Net Outflow Rankings - Yingfu Fund (02800) experienced the highest net outflow of -4.553 billion, with a -22.13% decrease, closing at 27.220 (+1.72%) [2] - Hang Seng China Enterprises (02828) had a net outflow of -1.380 billion, representing an -11.37% decrease, closing at 93.940 (+1.56%) [2] - Kuaishou-W (01024) faced a net outflow of -0.576 billion, with a -10.25% decrease, closing at 69.300 (-2.74%) [2] Net Inflow Ratio Rankings - Huaxia Hang Seng Technology (03088) led with a net inflow ratio of 90.53%, with a net inflow of 47.6883 million, closing at 6.875 (+1.33%) [3] - Southern East Selection (03441) followed with a net inflow ratio of 74.02%, with a net inflow of 18.0421 million, closing at 11.600 (+1.13%) [3] - Anhui Wantuo Expressway (00995) had a net inflow ratio of 68.27%, with a net inflow of 5.6553 million, closing at 13.340 (-0.07%) [3]

Core Insights - Southbound funds reduced their holdings in Baize Medical (02609.HK) by 1.5576 million shares on February 11, indicating a trend of net selling over the past five trading days, with a total net reduction of 775,800 shares [1] - Over the last 20 trading days, there were 11 days of net buying by southbound funds, accumulating to a total net increase of 6.9 million shares [1] - As of now, southbound funds hold 72.9198 million shares of Baize Medical, representing 5.52% of the company's total issued ordinary shares [1] Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also provides cancer diagnosis, treatment, rehabilitation, and end-of-life care, along with early cancer screening, cancer vaccination, and health management services for other potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Core Insights - The core viewpoint of the articles is that Baize Medical is innovating the healthcare model through its Hospital at Home (H@H) approach, which integrates value-based and digital healthcare, transforming traditional hospital operations into a technology-driven platform [1][5]. Group 1: Innovation in Healthcare Model - Baize Medical is pioneering the H@H model, which shifts the concept of hospitals from fixed locations to a more dynamic, patient-centered approach that actively engages with patients across different settings [1][6]. - The company has established a standardized operational system and AI-ready intelligent systems, enabling a transition from traditional hospital operations to a technology platform [1][5]. Group 2: Standardization in Medical Services - The lack of standardization in medical services has been a significant barrier to the scalable development of private healthcare. Baize Medical addresses this by transforming experience-based services into a standardized system that can be trained, assessed, and iterated [2]. - The company implements a "source standardization" strategy, embedding standardization into every aspect of healthcare operations, ensuring consistent quality and operational efficiency [2]. Group 3: Continuous Service Loop - The H@H model creates a seamless service loop from admission to home recovery, addressing the issue of patient disengagement post-discharge, thereby enhancing patient compliance, repurchase rates, and long-term loyalty [3]. - For example, in the case of surgical patients, the H@H model allows for continuous monitoring and personalized interventions, significantly improving patient outcomes and resource utilization [3]. Group 4: AI-Ready Data Assets - High-quality, standardized clinical data is crucial for the successful implementation of AI in healthcare. Baize Medical is building a comprehensive, time-sequenced medical data asset that positions it favorably in the industry [4]. - The company has achieved certification for its data assets in lung cancer diagnosis and tumor imaging, establishing a strong foundation for future data capitalization and AI model training [4]. Group 5: Business Model Transformation - Baize Medical's strategic direction focuses on creating a healthcare data asset layer, AI operational infrastructure, and a continuous health management business loop, aiming to transform traditional healthcare profitability models [5]. - This innovative model aligns with market preferences for platform-based healthcare enterprises with technological barriers, potentially capitalizing on the increasing share of commercial health insurance payments [5]. Group 6: Industry Trends and Opportunities - The H@H model is reshaping the rigid boundaries of traditional healthcare, extending services into homes and communities, thus addressing public concerns about access to care and rehabilitation [6]. - As commercial health insurance becomes a significant payment force, Baize Medical's innovative practices are expected to unlock growth potential and provide new pathways for the healthcare industry towards value-driven development [6].

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 327,000 shares on February 10, with a total net reduction of 64,200 shares over the past five trading days [1] - Over the last 20 trading days, there were 11 days of net increases in southbound fund holdings, totaling 7,309,800 shares [1] - As of now, southbound funds hold 74,477,400 shares of Baize Medical, representing 5.64% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 2.17 million shares on February 9, 2026, indicating growing investor interest in the company [1]. Group 1: Shareholding Changes - In the last 5 trading days, Baize Medical has seen a net increase of 3.31 million shares from southbound funds over 2 days [1]. - Over the past 20 trading days, there have been 11 days of net increases, totaling 7.16 million shares [1]. - As of February 9, 2026, southbound funds hold 74.80 million shares of Baize Medical, representing 5.66% of the company's total issued ordinary shares [1]. Group 2: Trading Data - On February 9, 2026, the total shareholding was 74.80 million, with a change of 2.17 million shares, reflecting a 3.00% increase [2]. - On February 6, 2026, the total shareholding was 72.63 million, with a decrease of 0.36 million shares, showing a -0.50% change [2]. - On February 5, 2026, the total shareholding was 72.99 million, with a decrease of 0.70 million shares, indicating a -0.96% change [2]. - On February 4, 2026, the total shareholding was 73.70 million, with a decrease of 0.84 million shares, reflecting a -1.13% change [2]. - On February 3, 2026, the total shareholding was 74.54 million, with an increase of 3.04 million shares, showing a 4.26% change [2]. Group 3: Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [2]. - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [2]. - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2].

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Baize Medical (02609.HK), indicating a reduction of 705,000 shares on February 5, while showing a net increase of 1,264,800 shares over the past five trading days [1] - Over the last 20 trading days, Baize Medical experienced net purchases from southbound funds on 12 occasions, totaling 7,593,600 shares [1] - As of now, southbound funds hold 72,990,600 shares of Baize Medical, representing 5.53% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services [1] - The company offers comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Group 1 - A total of 78 stocks reached a 52-week high as of February 3, with notable performers including Asia Pacific Financial Investments (08193) at 57.14%, Chao Wei Holdings (08059) at 36.00%, and Asia Backup (08290) at 33.33% [1] - The closing prices for the top three stocks that reached new highs were 0.550, 0.052, and 0.024 respectively, with their highest prices being 0.550, 0.068, and 0.036 [1] - Other significant stocks that reached new highs include Huameilele (08429) with a high rate of 20.37% and Haode Holdings (08149) at 17.65% [1] Group 2 - The report also lists stocks that reached 52-week lows, with the worst performer being Gaodi Holdings (01676) at -10.00%, followed by Huajian Medical (01931) at -9.29% and Electronic Trading Group (08036) at -9.09% [3] - The closing prices for the stocks that reached new lows include 0.340, 1.280, and 0.021 respectively, with their lowest prices being 0.315, 1.270, and 0.020 [3] - Other notable stocks that reached new lows include Controllon (01912) at -8.93% and Cool Link (08491) at -8.11% [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,318,466,823 | | | | 1,318,466,823 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,318,466,823 | | 0 | | 1,318,466,823 | 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | ...